Published in Cancer Weekly, April 4th, 2000
"We utilized the gene gun to transfect subcutaneous D5 melanoma and MT-901 mammary carcinoma tumors in situ with a granulocyte/macrophage-colony-stimulating factor (GM-CSF) plasmid complexed to gold particles," stated K. Tanigawa and colleagues from the University of Michigan, USA. "There was diminished tumor growth following bombardment with GM-CSF plasmid, which was apparent only during the period of administration."
Tanigawa et al. published the results of their study in the journal Cancer Immunology Immunotherapy ("Gene gun application in the generation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.